Table 2_Incidence and influencing factors of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung disease: a systematic review and meta-analysis.docx
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接:
https://figshare.com/articles/dataset/Table_2_Incidence_and_influencing_factors_of_progressive_pulmonary_fibrosis_in_connective_tissue_disease-associated_interstitial_lung_disease_a_systematic_review_and_meta-analysis_docx/31248136
下载链接
链接失效反馈官方服务:
资源简介:
BackgroundProgressive pulmonary fibrosis (PPF) is a major cause of poor prognosis in connective tissue disease-associated interstitial lung disease (CTD-ILD). This study aims to analyze and evaluate the incidence of PPF and related influencing factors in CTD-ILD.
MethodsWe searched PubMed, EMBASE, the Cochrane Library, Web of Science, and Scopus databases for studies on the incidence of PPF and influencing factors in CTD-ILD until August 20, 2025. The methodological quality of the included studies was assessed using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed using Stata 17.0 software.
ResultsA total of 22 studies were included in the meta-analysis, comprising 20 high-quality studies and 2 medium-quality studies. The incidence of PPF in CTD-ILD was 29% (95% CI: 25% - 34%). Meta-analysis identified Krebs von den Lungen-6 (KL-6: OR = 2.21, 95% CI: 1.24 - 3.94), human Surfactant Protein D (hSP-D: OR = 1.48, 95% CI: 1.16 - 1.90), Matrix Metalloproteinase-7 (MMP-7: OR = 1.48, 95% CI: 1.13 - 1.93), and Cancer Antigen 125 (CA-125: OR = 1.19, 95% CI: 1.05 - 1.34) as risk factors for PPF development. A higher baseline forced vital capacity percentage predicted value (FVC% predicted: OR = 0.98, 95% CI: 0.96 - 0.99) was identified as a protective factor against PPF development.
ConclusionsPatients with CTD-ILD are at high risk of developing PPF, and this progression risk is associated with KL-6, hSP-D, MMP-7, and CA-125. Identifying the incidence risk and influencing factors of PPF in CTD-ILD is crucial for early identification of high-risk populations, optimizing diagnostic and therapeutic strategies, and improving prognosis.
Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420251128274.
创建时间:
2026-02-04



